You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
NO
YES
Kedrion Biosc - Front Image

news

  1. 25-08-2017

    Kedrion Biopharma and Kamada Ltd Receive FDA Approval for KEDRAB®

    The product is approved for post-exposure prophylaxis against rabies infection

    read more 
  2. 11-08-2017

    First half results 2017

    First half consolidated turnover of EUR 271.7 M and adjusted EBITDA increase by 29.0% compared to the same period in 2016, with a margin of 24.1%

    read more 
  3. 12-07-2017

    Result of cash tender offer for Notes due 24 april 2019

    The Company hereby announces to accept for purchase Notes validly tendered pursuant to the Offer for a total aggregate principal amount equal to €91,080,000

    read more 
  4. 05-07-2017

    Launch of new 350 Million Bond and tender offer indicative results

    Kedrion successfully completed pricing of new Euro 350 M notes due July 2022 and tender offer for notes due April 2019

    read more 
  5. 27-06-2017

    Cash Tender Offer for Notes due 24 April 2019

    Tender Offer for €300,000,000 4.625 per cent. Notes due 24 April 2019

    read more 
  6. 31-03-2017

    Annual Results 2016

    Consolidated turnover of 659.3 million Euro, a growth of 89 million Euro or 15.6%

    read more 
  7. 29-09-2015

    Kedrion Notes 2019 Tender Offer results

    Kedrion has decided to accept for purchase Notes validly tendered for a total aggregate principal amount equal to €150,716,000

    read more 
  8. 21-09-2015

    Cash Tender Offer for Notes due 24 April 2019

    Kedrion S.p.A. announced Cash Tender Offer for its €300,000,000 4.625 per cent. outstanding Notes due 24 April 2019.

    read more 
  9. 12-11-2014

    Kedrion joins the programme “ELITE for Large Corporates”

    Launched by Borsa Italiana, ELITE is targeted to companies aiming at strengthening their global leadership

    read more 
  10. 15-10-2014

    New generation immunoglobulins: in January production of clinical batches

    The first batch for the feasibility test was produced at the Gödöllő plant in September with results in compliance with specifications

    read more 

Pages

For more information please contact: investor@kedrion.com